Brief: OSE, Boehringer Ingelheim To Develop Treatments For Cancer And CRM Diseases

Ose Immunotherapeutics SA

22/05/2024 06:49

May 22 (Reuters) - OSE Immunotherapeutics SA  OSE.PA :
    * OSE IMMUNOTHERAPEUTICS AND BOEHRINGER INGELHEIM EXPAND
COLLABORATION TO DEVELOP FIRST-IN-CLASS TREATMENTS FOR CANCER
AND CARDIO-RENAL-METABOLIC DISEASES
    * WILL RECEIVE EUR 13.5. MLN IN UPFRONT PAYMENT
    * POTENTIAL NEAR-TERM MILESTONE OF EUR 17.5 MLN FOR PURCHASE
OF A
NOVEL, CIS-TARGETING ANTI-PD-1/CYTOKINE ASSET IN PRECLINICAL
STAGE
    * REGARDING ONGOING ANTI-SIRPΑ PROGRAMS PARTIES AGREED ON
PARTIAL
ROYALTY BUY-OUT MONETIZING WITH A PAYMENT OF EUR 25.3 MLN

Source text for Workspqce:  ID:nGNX1Tr7Bw 
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))